Compumedics Ltd (ASX:CMP) chairman Dr David Burton and CFO David Lawson speak with Proactive following news the US Food & Drug Administration (FDA) has cleared the company’s Somfit device to be marketed in the USA. They say it marks the achievement of another significant strategic milestone for the Somfit technology platform in one of the world’s largest sleep markets. The home sleep testing (HST) market in the USA, which the Somfit is primarily targeted at, is estimated to be about two million studies per year.
Compumedics Ltd CFO and executive director David Lawson and executive chairman and CEO David Burton sat down with Proactive’s Andrew Scott to discuss the major milestone surrounding its Somfit technology platform. Somfit® has received FDA clearance for the device to be marketed in the USA.
There is a significant addressable market in the USA between US$110 million to US$180 million in potential revenue, which Compumedics will target 10% to 30% of within the next 24 months. Compumedics can now begin its commercialisation activities in the key USA market, following the initial successful validation and commencement of sales activities for Somfit in the Australian market, since the beginning of the 2024 financial year.
In commenting on this significant milestone for Compumedics, David Burton said when the announcement came out, “Following FDA clearance for the Somfit device in the USA, Compumedics can now begin executing their commercialisation strategy to capitalise on the under-penetrated sleep market with an initial focus on Home Sleep Testing (HST), before addressing other opportunities.”
Contact Details
Proactive Investors
Jonathan Jackson
+61 413 713 744
jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source Press Releases
Compumedics Limited is a medical device company, which is involved in the development, manufacture, and commercialization of diagnostics technology for sleep, brain and ultrasonic blood flow monitoring applications. Its geographic segments include Americas, Australia and Asia Pacific, and Europe and the Middle East. It sells all of its product offerings in this region, including sleep diagnostic systems, clinical EEG systems, brain monitoring systems, ultra-sonic blood-flow systems, supplies and technical service and support. It provides Sleep Diagnostics and Neurology Diagnostics Solutions. Its products include Compumedics Siesta, Compumedics Somfit, Compumedics Somte PSG and others. It offers Brain Research technologies through the Compumedics Neuroscan brand. Compumedics Neuroscan technologies provide solutions for EEG, ERPs, Source Localization and Functional Neuroimaging. It also provides solutions for sleep applications from high definition 4k full PSG to home sleep testing.